home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S - From 05/15/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
Should You Hold Viking Therapeutics in Your Portfolio? | Benzinga

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has be...
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms | Benzinga

Novo Nordisk A/S (NYSE:NVO) says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does n...

Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound | Benzinga

Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popu...

Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments | Benzinga

Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over...
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency | Benzinga

Monday, Novo Nordisk A/S (NYSE:NVO) released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthl...

'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem | Benzinga

Tesla and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his...

Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro | Benzinga

Online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk A/S’s (NYSE:NVO) Wegovy and&n...
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition | Benzinga

Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase com...

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca | Benzinga

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...

Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic | Benzinga

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier...
Previous 10 Next 10